| Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? |
The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-05-16 15:01:13 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for May 8th |
BTSG, NWFL, MNRO, UBSI and IMCR have been added to the Zacks Rank #1 (Strong Buy) List on May 8, 2025. |
zacks.com |
2025-05-08 12:36:07 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics |
The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-05-07 14:36:39 |
Czytaj oryginał (ang.) |
| Immunocore reports first quarter financial results and provides a business update |
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-30 15:00:33 |
Czytaj oryginał (ang.) |
| Immunocore to present at upcoming investor conferences |
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md. |
globenewswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Insiders Make Huge Purchases of These 4 Biotech Stocks |
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations. |
247wallst.com |
2025-03-26 10:40:53 |
Czytaj oryginał (ang.) |
| Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? |
Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-03-21 13:25:25 |
Czytaj oryginał (ang.) |
| Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 |
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 |
globenewswire.com |
2025-03-10 17:00:00 |
Czytaj oryginał (ang.) |
| Immunocore to present at upcoming investor conferences |
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in March. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point |
Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Growth of tebentafusp sales has slowed, increasing reliance on new projects like brenetafusp, which carries inherent biotech industry risks. |
seekingalpha.com |
2025-02-27 10:11:08 |
Czytaj oryginał (ang.) |
| Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript |
Immunocore Holdings plc (NASDAQ:IMCR ) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Corporate Development Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Michael Yee - Jefferies Jessica Fye - JPMorgan Tyler Van Buren - TD Cowen Eric Schmidt - Cantor Fitzgerald Justin Zelin - BTIG Jonathan Chang - Leerink Partners Ethan Markowski - Needham & Company Peter Lawson - Barclays Patrick Trucchio - H.C. Wainwright Rajan Sharma - Goldman Sachs David Dai - UBS Jeff Jones - Oppenheimer Operator Greetings and welcome to the Immunocore Conference Call and Webcast. |
seekingalpha.com |
2025-02-26 15:24:05 |
Czytaj oryginał (ang.) |
| Immunocore reports fourth quarter and full year 2024 financial results and provides a business update |
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025 |
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, February 26, 2025. |
globenewswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? |
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak. |
zacks.com |
2025-02-17 13:26:13 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-01-13 12:55:29 |
Czytaj oryginał (ang.) |
| Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference |
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration |
globenewswire.com |
2025-01-10 09:00:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 7th |
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024. |
zacks.com |
2025-01-07 10:21:11 |
Czytaj oryginał (ang.) |
| Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference |
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. |
globenewswire.com |
2025-01-06 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development |
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development |
globenewswire.com |
2025-01-02 09:00:00 |
Czytaj oryginał (ang.) |
| 3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 |
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025. |
zacks.com |
2024-12-26 16:10:23 |
Czytaj oryginał (ang.) |
| Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term |
These five geonomics and synthetic biology stocks are likely to soar in the short-term. They Are: CRSP, IMCR, GLUE, RIGL, CSTL. |
zacks.com |
2024-12-23 10:50:17 |
Czytaj oryginał (ang.) |
| Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME |
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME |
globenewswire.com |
2024-12-23 09:00:00 |
Czytaj oryginał (ang.) |
| Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? |
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. |
benzinga.com |
2024-12-13 16:10:50 |
Czytaj oryginał (ang.) |
| All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy |
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
zacks.com |
2024-12-12 15:06:18 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 12th |
NBBK, OMCL, ZIM, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on December 12, 2024. |
zacks.com |
2024-12-12 09:21:22 |
Czytaj oryginał (ang.) |
| Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma |
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma |
globenewswire.com |
2024-12-03 03:00:00 |
Czytaj oryginał (ang.) |
| Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-28 13:01:27 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for November 26th |
ZIM, MNDY, RSI, IMCR and ULS have been added to the Zacks Rank #1 (Strong Buy) List on November 26, 2024. |
zacks.com |
2024-11-26 09:26:14 |
Czytaj oryginał (ang.) |
| 3 Fast-Growing Stocks Analysts See Doubling in Price |
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise. |
marketbeat.com |
2024-11-11 09:16:18 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know |
The average of price targets set by Wall Street analysts indicates a potential upside of 112.6% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-08 12:55:23 |
Czytaj oryginał (ang.) |
| Immunocore to present at upcoming investor conferences |
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November. |
globenewswire.com |
2024-11-08 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore reports third quarter financial results and provides a business update |
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md. |
globenewswire.com |
2024-11-06 09:00:00 |
Czytaj oryginał (ang.) |
| Immunocore (IMCR) Upgraded to Buy: Here's Why |
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-11-05 15:00:45 |
Czytaj oryginał (ang.) |
| Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer |
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer |
globenewswire.com |
2024-09-14 07:00:00 |
Czytaj oryginał (ang.) |
| Immunocore to present at the 2024 Cantor Global Healthcare Conference |
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md. |
globenewswire.com |
2024-09-12 20:05:00 |
Czytaj oryginał (ang.) |
| Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak |
In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference. |
seekingalpha.com |
2024-08-30 15:40:32 |
Czytaj oryginał (ang.) |
| Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal |
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V. |
seekingalpha.com |
2024-08-12 08:12:40 |
Czytaj oryginał (ang.) |
| Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript |
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-11 10:53:06 |
Czytaj oryginał (ang.) |